XTL Biopharmaceuticals Ltd (H2K2) - Total Liabilities

Latest as of December 2024: €3.12 Million EUR ≈ $3.64 Million USD

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (H2K2) has total liabilities worth €3.12 Million EUR (≈ $3.64 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

XTL Biopharmaceuticals Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of XTL Biopharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.

XTL Biopharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Liberty Tripadvisor Holdings Inc NASDAQ:LTRPB	USA	$2.22 Billion
Lyra Therapeutics Inc NASDAQ:LYRA	USA	$46.83 Million
Composite Alliance Group Inc V:CAG	Canada	CA$25.07 Million
Interactive Strength Inc. Common Stock NASDAQ:TRNR	USA	$40.45 Million
New Star Investment Trust plc LSE:NSI	UK	GBX318.00K
Awareness Group NASDAQ:TAAG	USA	$30.92 Million
Global Opportunities Trust Ord LSE:GOT	UK	GBX170.00K

Liability Composition Analysis (2016–2024)

This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is XTL Biopharmaceuticals Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.61	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.57	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2016–2024)

The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€3.12 Million ≈ $3.64 Million	+1412.14%
2023-12-31	€206.00K ≈ $240.84K	+10.16%
2022-12-31	€187.00K ≈ $218.62K	-85.45%
2021-12-31	€1.28 Million ≈ $1.50 Million	+405.91%
2020-12-31	€254.00K ≈ $296.95K	+9.48%
2019-12-31	€232.00K ≈ $271.23K	-8.30%
2018-12-31	€253.00K ≈ $295.78K	-91.47%
2017-12-31	€2.97 Million ≈ $3.47 Million	+799.09%
2016-12-31	€330.00K ≈ $385.80K	--

About XTL Biopharmaceuticals Ltd

F:H2K2 Germany Biotechnology

Market Cap

$6.31 Million

€5.39 Million EUR

Market Cap Rank

#30399 Global

#2676 in Germany

Share Price

€2.28

Change (1 day)

+23.24%

52-Week Range

€0.45 - €2.80

All Time High

€8.26